METTL3 and colorectal carcinoma: Further, CRC patients with increased expression of METTL3 (Fig. 8L), RRM2B (Fig. 8M), OPA1 (Fig. 8N) and IGF2BP2 (Fig. S8G) showed reduced overall survival (OS).